News
DRRX
0.8020
+0.25%
0.0020
Weekly Report: what happened at DRRX last week (0324-0328)?
Weekly Report · 2d ago
Oppenheimer Sticks to Its Buy Rating for Durect (DRRX)
TipRanks · 3d ago
DURECT Corporation’s Earnings Call Highlights Cost Cuts and Breakthrough Potential
TipRanks · 5d ago
DURECT CORPORATION ANNUAL REPORT ON FORM 10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024
Press release · 6d ago
HC Wainwright & Co. Reiterates Neutral on Durectto Neutral
Benzinga · 6d ago
H.C. Wainwright Sticks to Its Hold Rating for Durect (DRRX)
TipRanks · 6d ago
Northland Securities Reaffirms Their Buy Rating on Durect (DRRX)
TipRanks · 6d ago
DURECT Corporation Reports 2024 Financial Results and Updates
TipRanks · 6d ago
DURECT outlines $20M Phase 3 trial for larsucosterol in alcohol-associated hepatitis
Seeking Alpha · 6d ago
Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates
NASDAQ · 03/26 21:20
Durect reports Q4 cont ops EPS (6c), consensus (2c)
TipRanks · 03/26 20:11
DURECT GAAP EPS of $0.24, revenue of $0.45M
Seeking Alpha · 03/26 20:08
*Durect 4Q Net $7.75M >DRRX
Dow Jones · 03/26 20:05
*Durect 4Q Rev $453,000 >DRRX
Dow Jones · 03/26 20:05
*Durect 4Q EPS 24c >DRRX
Dow Jones · 03/26 20:05
Press Release: DURECT Corporation Reports Fourth -2-
Dow Jones · 03/26 20:05
Durect: Q4 Earnings Snapshot
Barchart · 03/26 15:21
Here are the major earnings after the close today
Seeking Alpha · 03/26 14:00
Options Volatility and Implied Earnings Moves Today, March 26, 2025
TipRanks · 03/26 12:05
Earnings Scheduled For March 26, 2025
Benzinga · 03/26 08:32
More
Webull provides a variety of real-time DRRX stock news. You can receive the latest news about DURECT through multiple platforms. This information may help you make smarter investment decisions.
About DRRX
More
DURECT Corporation is a late-stage biopharmaceutical company. The Company is engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcoholic hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Therapy designation, and metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. Its commercial pharmaceutical product includes POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology. It has also completed Alcohol-Associated Hepatitis (AHFIRM) Phase 2b study.